Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amylin Pharmaceuticals has sued Eli Lilly in the US District Court for the Southern District of California.
Subscribe to our email newsletter
The lawsuit alleged that Eli Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.
The agreement was originally signed in 2002 to develop and commercialize exenatide.
Exenatide is a medicine indicated as a treatment for type 2 diabetes that is currently marketed as Byetta (exenatide) injection.
The plaintiff has said Lilly is engaging in improper, unlawful and anticompetitive behavior in the manner in which it plans to implement its recently announced global alliance agreement with Boehringer Ingelheim to jointly develop and commercialize BI’s linagliptin product, which will compete directly with Amylin’s exenatide products.
Amylin said notwithstanding this litigation, we intend to continue to collaborate with Lilly in the development and commercialization of exenatide products.